These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 3521247)
1. Treatment of hyperlipidemia. Gotto AM Am J Cardiol; 1986 May; 57(14):11G-16G. PubMed ID: 3521247 [TBL] [Abstract][Full Text] [Related]
2. Role of risk factor management in progression and regression of coronary and femoral artery atherosclerosis. Glueck CJ Am J Cardiol; 1986 May; 57(14):35G-41G. PubMed ID: 3521250 [TBL] [Abstract][Full Text] [Related]
3. Prevention of progression of coronary atherosclerosis by treatment of hyperlipidaemia: a seven year prospective angiographic study. Nikkilä EA; Viikinkoski P; Valle M; Frick MH Br Med J (Clin Res Ed); 1984 Jul; 289(6439):220-3. PubMed ID: 6430414 [TBL] [Abstract][Full Text] [Related]
5. Hyperlipidemia: perspectives in diagnosis and treatment. Yeshurun D; Gotto AM South Med J; 1995 Apr; 88(4):379-91. PubMed ID: 7716588 [TBL] [Abstract][Full Text] [Related]
6. Rationale for treatment. Gotto AM Am J Med; 1991 Jul; 91(1B):31S-36S. PubMed ID: 1867234 [TBL] [Abstract][Full Text] [Related]
8. Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol. Rubins HB; Robins SJ; Iwane MK; Boden WE; Elam MB; Fye CL; Gordon DJ; Schaefer EJ; Schectman G; Wittes JT Am J Cardiol; 1993 Jan; 71(1):45-52. PubMed ID: 8420235 [TBL] [Abstract][Full Text] [Related]
9. The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of NHLBI Type II Coronary Intervention Study. Levy RI; Brensike JF; Epstein SE; Kelsey SF; Passamani ER; Richardson JM; Loh IK; Stone NJ; Aldrich RF; Battaglini JW Circulation; 1984 Feb; 69(2):325-37. PubMed ID: 6360415 [TBL] [Abstract][Full Text] [Related]
10. Guidelines for the detection of high-risk lipoprotein profiles and the treatment of dyslipoproteinemias. Canadian Lipoprotein Conference Ad Hoc Committee on Guidelines for Dyslipoproteinemias. CMAJ; 1990 Jun; 142(12):1371-82. PubMed ID: 2190685 [TBL] [Abstract][Full Text] [Related]
11. Atherogenic lipoprotein profile in families with and without history of early myocardial infarction. Dobiásová M; Raslová K; Rauchová H; Vohnout B; Ptácková K; Frohlich J Physiol Res; 2001; 50(1):1-8. PubMed ID: 11300220 [TBL] [Abstract][Full Text] [Related]
12. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial). Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227 [TBL] [Abstract][Full Text] [Related]
13. Triglyceride as a risk factor for coronary artery disease. Gotto AM Am J Cardiol; 1998 Nov; 82(9A):22Q-25Q. PubMed ID: 9819100 [TBL] [Abstract][Full Text] [Related]
14. Changing perspectives in the prevention of coronary artery disease. Levy RI Am J Cardiol; 1986 May; 57(14):17G-26G. PubMed ID: 3087152 [TBL] [Abstract][Full Text] [Related]
15. A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly. Li JZ; Chen ML; Wang S; Dong J; Zeng P; Hou LW Chin Med J (Engl); 2004 Feb; 117(2):163-7. PubMed ID: 14975195 [TBL] [Abstract][Full Text] [Related]
16. Low-density lipoproteins and risk for coronary artery disease. Ballantyne CM Am J Cardiol; 1998 Nov; 82(9A):3Q-12Q. PubMed ID: 9819098 [TBL] [Abstract][Full Text] [Related]
17. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA; 1984 Jan; 251(3):365-74. PubMed ID: 6361300 [TBL] [Abstract][Full Text] [Related]
18. Prognostic and therapeutic significance of low levels of high-density lipoprotein cholesterol: current perspectives. Gotto AM Arch Intern Med; 1999 May; 159(10):1038-40. PubMed ID: 10335679 [No Abstract] [Full Text] [Related]
19. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group. Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751 [TBL] [Abstract][Full Text] [Related]
20. Secondary prevention and lipid lowering: results and implications. Detre KM; Levy RI; Kelsey SF; Epstein SE; Brensike JF; Passamani ER; Richardson JM; Loh IK; Stone NJ; Aldrich RF Am Heart J; 1985 Nov; 110(5):1123-7. PubMed ID: 3904378 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]